Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry. Register now to see our 7 Best Stocks for the Next 30 Days report - free today! Amgen (AMGN) , in a press release, dismissed recent concerns that its obesity candidate, MariTide, may cause loss of bone mineral density ("BMD"). Some analysts at a global financial services firm claimed that a revie ...